VBIO - Vitality Biopharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2400
0.0000 (0.00%)
As of 3:42PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2400
Open0.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2400 - 0.2400
52 Week Range0.0400 - 2.3300
Volume5,277
Avg. Volume19,250
Market Cap12.775M
Beta (3Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.1780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.40
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Vitality Biopharma Welcomes New Executive Management Team

    Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the resignation of CEO and director Robert Brooke, the appointment of current board member Michael Cavanaugh as Vitality’s interim CEO and the promotion of current Controller and Counsel Richard McKilligan to CFO and Counsel. Mr. Brooke, a bioengineer by training, was a co-founder of the Company along with recently-departed director Dr. Avtar Dhillon.  Mr. Brooke plans to focus on private biotechnology ventures as well as non-profit patient advocacy and disease research initiatives.

  • GlobeNewswire2 months ago

    Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors

    Dr. Dhillon was a co-founder of the Company along with Vitality’s current CEO Robert Brooke, and he has previously served as its Chairman and as a Director.  He departs to focus on other professional interests including a senior management role with a licensed medical cannabis producer in Canada. “It has been a pleasure for me to have been a co-founder of Vitality and to help build it to its current stage.

  • GlobeNewswire5 months ago

    Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board

    LOS ANGELES, Jan. 24, 2019 -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of.

  • GlobeNewswire6 months ago

    Vitality Biopharma to Present at the 11th Annual LD Micro Main Event

    Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 11th Annual LD Micro Main Event in Los Angeles. The corporate presentation is on Wednesday, December 5, 2018 at 12:00 PM Pacific/3:00 PM Eastern. Mr. Robert Brooke, CEO of Vitality, will be giving the presentation and meeting with investors during the event.

  • GlobeNewswire7 months ago

    Vitality Biopharma Announces Corporate Updates and Completion of an SEC Examination

    Company appoints two new directors including the Hon. LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced corporate updates, the appointment of two new directors including a new Chairman of the Board, and the completion of an SEC examination.

  • ACCESSWIRE7 months ago

    SeeThruEquity Issues Update on Vitality Biopharma (VBIO) with Target Price of $3.50

    NEW YORK, NY / ACCESSWIRE / November 7, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Vitality Biopharma, Inc. (VBIO) with a Target Price of $3.50. Vitality Biopharma, Inc. (OTCQB: VBIO, ''Vitality'') is focused on the development of cannabinoids for the treatment of serious neurological and inflammatory disorders, as well as pain and opioid addiction. Vitality's development pipeline is focused on a new class of cannabinoid prodrug pharmaceuticals called cannabosides.

  • ACCESSWIRE8 months ago

    Vitality Biopharma Tackling the Medical Benefits of Cannabis with a Diverse Pipeline

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vitality Biopharma, Inc. (VBIO), a cure development company, dedicated to unlocking the power of cannabinoid "prodrugs" as a means to treat serious neurological and inflammatory disorders.